NCT01684189

Brief Summary

Objectives：

  1. 1.To assess the percentage of febrile neutropenia and suspected fungal-related febrile episodes in patients receiving chemotherapy
  2. 2.To explore the percentage/distribution of infectious origins of febrile neutropenia
  3. 3.To explore the percentage/distribution of infectious pathogens of febrile neutropenia
  4. 4.To explore clinical outcomes of different infectious origins/pathogens in febrile neutropenia episodes
  5. 5.To have a clear view of therapeutic actions in the management of hematological patients with febrile neutropenia and suspected fungal-related febrile episodes

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
100

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Nov 2011

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2011

Completed
10 months until next milestone

First Submitted

Initial submission to the registry

September 10, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 12, 2012

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2013

Completed
Last Updated

September 12, 2012

Status Verified

November 1, 2011

First QC Date

September 10, 2012

Last Update Submit

September 11, 2012

Conditions

Hematological DiseaseFebrile NeutropeniaFungal Infections

Study Arms (1)

Patient registry

Patients with newly diagnosed malignant hematological diseases will be enrolled into this registry

Other: Patient registry

Interventions

Patient registryOTHER

Patient registry without study intervention

Patient registry

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients with newly diagnosed malignant hematological diseases

You may qualify if:

  • Patients with new diagnosed hematological diseases (acute and chronic myeloid and lymphoid leukemia, multiple myeloma, non-Hodgkin's and Hodgkin's lymphoma, myelodysplastic syndromes)
  • Patients who are receiving chemotherapy and have ongoing febrile episodes

You may not qualify if:

  • None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Kaohsiung Chang Gung Memorial Hospital

Kaohsiung City, 833, Taiwan

RECRUITING

MeSH Terms

Conditions

Hematologic DiseasesFebrile NeutropeniaMycoses

Condition Hierarchy (Ancestors)

Hemic and Lymphatic DiseasesNeutropeniaAgranulocytosisLeukopeniaCytopeniaLeukocyte DisordersBacterial Infections and MycosesInfections

Study Officials

  • Ming-Chung Wang, M.D.

    Chang Gung Memorial Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Ming-Chung Wang, M.D.

CONTACT

+886-7-7317123wang9595@ms32.hinet.net

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 10, 2012

First Posted

September 12, 2012

Study Start

November 1, 2011

Study Completion

August 1, 2013

Last Updated

September 12, 2012

Record last verified: 2011-11

Locations

TW(1)